National Institute of Environmental Health Sciences; Notice of Closed Meetings, 18040 [2014-07021]
Download as PDF
<![CDATA[
18040
Federal Register / Vol. 79, No. 61 / Monday, March 31, 2014 / Notices
on February 3, 2011, PCT Application
Number PCT/US2012/23575, filed on
February 2, 2012, U.S. Patent
Application Number 13/983,545, filed
on August 2, 2013, European Patent
Application Number 12702953.6, filed
on February 2, 2012, and Canadian
Patent Application Number 2826594,
filed on February 2, 2012, to Exxell BIO,
Inc., having a place of business in
Shoreview, Minnesota, United States of
America. The patent rights in these
inventions have been assigned to the
United States of America and Thomas
Jefferson University.
Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before April
30, 2014 will be considered.
DATES:
Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Peter Soukas, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Email:
ps193c@nih.gov; Telephone: (301) 435–
4646; Facsimile: (301) 402–0220.
ADDRESSES:
No
vaccine candidates against Ebola virus
(EBOV) or Marburg virus (MARV) are
nearing licensure, and the need to
develop a safe and efficacious vaccine
against filoviruses continues. Whereas
several preclinical and clinical vaccine
candidates against EBOV or MARV exist
(please see below for further
elaboration), their further development
is a major challenge based on safety
concerns, pre-existing vector immunity,
issues such as manufacturing, dosage,
and marketability, and funding for
development. The inventors have
developed a new platform based on live
or chemically inactivated (killed) rabies
virus (RABV) virions containing EBOV
glycoprotein (GP) in their envelope. In
preclinical trials, immunization with
such recombinant RABV virions
provided excellent protection in mice
against lethal challenge with the mouse
adapted EBOV and RABV. More
specifically, the inventors have
developed a trivalent filovirus vaccine
based on killed rabies virus virions for
use in humans to confer protection from
all medically relevant filoviruses and
RABV. Two additional vectors
containing EBOV Sudan GP or MARV
GP are planned to be constructed in
addition to the previously developed
EBOV Zaire GP containing vaccine. Live
attenuated vaccines have been
developed for use in at risk nonhuman
primate populations in Africa and
tkelley on DSK3SPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
18:10 Mar 28, 2014
Jkt 232001
inactivated vaccines have been
developed for use in humans.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published Notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.
The fields of use may be limited to (1)
inactivated vaccines against rabies virus
and filoviruses for use in humans and
(2) live attenuated vaccines against
rabies virus and filoviruses for use in
non-human animals.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 26, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–07023 Filed 3–28–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
contract proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications
and contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Emphasis Panel; NIH Loan Repayment
Program (Clinical and Pediatric Researchers).
Date: April 24, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Room 3094, Morrisville, NC
27560; (Virtual Meeting).
Contact Person: RoseAnne M. McGee,
Associate Scientific Review Administrator,
Scientific Review Branch, Division of
Extramural Research and Training, Nat.
Institute of Environmental Health Sciences,
P.O. Box 12233, MD EC–30, Research
Triangle Park, NC 27709, (919) 541–0752,
mcgee1@niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Career Grant Applications
Review in Environmental Health Sciences.
Date: April 24, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Room 3118, Morrisville, NC
27560, (Telephone Conference Call).
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research and Training, Nat. Institute of
Environmental Health Sciences, P.O. Box
12233, MD EC–30/Room 3171, Research
Triangle Park, NC 27709, (919) 541–0670,
worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: March 25, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–07021 Filed 3–28–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Center for Advancing Translational
Sciences.
E:\FR\FM\31MRN1.SGM
31MRN1
]]>Agencies
[Federal Register Volume 79, Number 61 (Monday, March 31, 2014)]
[Notices]
[Page 18040]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07021]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Environmental Health Sciences; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and contract proposals and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications and
contract proposals, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Institute of Environmental Health
Sciences Special Emphasis Panel; NIH Loan Repayment Program
(Clinical and Pediatric Researchers).
Date: April 24, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Environmental Health Sciences,
Keystone Building, 530 Davis Drive, Room 3094, Morrisville, NC
27560; (Virtual Meeting).
Contact Person: RoseAnne M. McGee, Associate Scientific Review
Administrator, Scientific Review Branch, Division of Extramural
Research and Training, Nat. Institute of Environmental Health
Sciences, P.O. Box 12233, MD EC-30, Research Triangle Park, NC
27709, (919) 541-0752, mcgee1@niehs.nih.gov.
Name of Committee: National Institute of Environmental Health
Sciences Special Emphasis Panel; Career Grant Applications Review in
Environmental Health Sciences.
Date: April 24, 2014.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Environmental Health Sciences,
Keystone Building, 530 Davis Drive, Room 3118, Morrisville, NC
27560, (Telephone Conference Call).
Contact Person: Leroy Worth, Ph.D., Scientific Review
Administrator, Scientific Review Branch, Division of Extramural
Research and Training, Nat. Institute of Environmental Health
Sciences, P.O. Box 12233, MD EC-30/Room 3171, Research Triangle
Park, NC 27709, (919) 541-0670, worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.115,
Biometry and Risk Estimation--Health Risks from Environmental
Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund Hazardous Substances--Basic
Research and Education; 93.894, Resources and Manpower Development
in the Environmental Health Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114, Applied Toxicological Research
and Testing, National Institutes of Health, HHS)
Dated: March 25, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-07021 Filed 3-28-14; 8:45 am]
BILLING CODE 4140-01-P
